Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Com	plete if Known
Substitute f	or form 144	9/PTO	1	Application Number	10/698,983
INFORM	IATION	DISC	CLOSURE	Filing Date	October 31, 2003
			PLICANT	First Named Inventor	Howard Sands
(Use a	as many shec	is as ne	cessary)	Art Unit	1615
				Examiner Name	Carlos A. Azpuru
Sheet	1	of	1	Attorney Docket Number	12636-304.201

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/S.G.L/	•	BROWN, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther. 2004; 4(4): 501-510.	
/S.G.L/		GILBERT, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation. Clinical Cancer Research. 2004; 10: 4589-4596.	
/S.G.L/		HERMAN, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation. The New England Journal of Medicine. 2003; 349(21): 2042-2054.	
/S.G.L/	,	LEONE, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. <i>Haematologica</i> . 2002; 87(12): 1324-1341.	
/S.G.L	/	LEONE, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003; 109(1): 89-102.	

Examiner	/Sharmila Landau/	Date	07/02/2007
signature		Considered	07/03/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

	Con	nplete if Known
	Application Number	10/698,983
	Filing Date	October 31, 2003
	First Named Inventor	Howard Sands et al.
	Art Unit	1614
	Examiner Name	Not yet assigned
_	Attorney Docket Number	12636-304.201

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
/S.G.L/		US- 6,248,363	06/19/2001	Lipocine, Inc.			
76.55		US-					
		US-					
		US-		·			
		US-	<u> </u>				
		US-					
		US-		·			
_		US-					
		US-					
		US-			······································		
		US-					
		US-			·		
· · · · · · · · · · · · · · · · · · ·		US-			· · · · · · · · · · · · · · · · · · ·		
		US-	· ·	,	······································		
		US-			······································		
		US-	 				
		US-					
		US-		†			
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te			
		Country Code' - Number' - Kind Code' (if known)				 			
·				·	ļ	ļ			
						1			
						1			

Examiner Signature	/Sharmila Landau/	Date Considered	07/03/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Mr	rit in the second secon		Com	Complete if Known		
Substitute fo	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/698,983		
INFORM			Filing Date	10/31/2003		
			First Named Inventor	Howard Sands		
(Use as	s many sheet.	s as ne	cessary)	Art Unit	1614	
			Examiner Name	Not yet assigned		
Sheet	1	of	5	Attorney Docket Number	12636-304.201	

		U.S. PA	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/S.G.L/		US-2001/0012835 A1	04/14/1997	Fine, et al.	
		US-2002/0114809 A1	02/21/2001	Rubinfeld, et al.	
		US-2002/0136709 A1	07/31/2001	Zahner	
		US-2003/0013099 A1	03/19/2001	Lasek, et al.	
		US-2003/0039689 A1	04/26/2002	Chen, et al.	
		US-2003/0045497 A1	07/26/2002	Widegren, et al.	
		US-2003/0108588 A1	09/17/2002	Chen, et al.	
		US-2003/0147813 A1	02/07/2002	Lyons	
1		US-2003/0165864 A1	01/16/2002	Lasek, et al.	
		US-2003/0171303 A1	06/11/2002	Gallop, et al.	
		US-2003/0229047 A1	06/05/2002	Joshi-Hangal, et al.	
		US-4,690,918	09/01/1987	Beppu, et al.	
		US-5,736,531	12/30/1993	Von Borstel, et al.	
		US-5,856,090	09/09/1994	Epstein	
		US-5,856,094	06/30/1995	Sidransky, et al.	
		US-5,968,914	10/28/1987	Von Borstel, et al.	•
\/		US-6,136,791	12/23/1996	Nyce	
/S.G.L/		US-6,255,293 B1	07/24/1998	Kimchi	

				07/03/2007
1	Examiner	/Chamila Landau/	Date	07/00/0007
1	Signature	/Sharmila Landau/	Considered	07/03/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE				Application Number	10/698,983	
			LOSURE	Filing Date	10/31/2003	
	STATEMENT BY APPLICANT		First Named Inventor	Howard Sands		
(Use a	s many shee	ts as nec	cessary)	Art Unit	1614	
				Examiner Name	Not yet assigned	
Sheet	2	of	5	Attorney Docket Number	12636-304.201	

		FOREIGN	PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	Т
		Country Code' - Number' - Kind Code' (If trawn) CS 269077	12/22/1963	Ceskoslovenska	Relevant Figures Appear	┝
/S.G.L/		CS 209077	12/22/1903	akademie ved, (Prag)	·	
<u> </u>		DE 1922702	05/03/1969	Ceskoslovenska		├
] [DE 1922/02	03/03/1909	akademie ved, (Prag)		
		DE 2105468	02/05/1971	Ceskoslovenska		┝
		DE 2103408	02/03/19/1	akademie ved, (Prag)		
		EP 286958	04/06/1988	Merck Pg		\vdash
—		JP 05219974	02/13/1992	Mitsui Petrochem Ind		\vdash
		31 03213374	02/13/17/2	Lid		
		JP 2002223753	01/30/2001	Hitachi		Ι.
		JP 2002370939	06/12/2001	Taisho Pharmaceutical		-
1		1. 200237033	00,12,2001	Co. Ltd.		
		JP 2003310293	04/26/2002	Mitsui Chemical Inc.		✝
		PCT/US04/22367	07/20/2005	SuperGen, Inc.		t
1		International Search Report				
		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		Τ
		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		1
		WO 94/27632	06/01/1993	Nycomed Pharma A/S		T
		WO 96/11280	10/07/1994	East Carolina		T
		,		University		
		WO 96/36693	05/19/1995	Phytera, Inc.		
		WO 96/39035	06/06/1995	Case Western Reserve		T
				Unniversity		
	,	WO 96/40165	06/07/1995	Pro-Neuron, Inc.		Γ
		WO 98/14619	10/03/1996	Incyte		
				Pharmaceuticals, Inc.		
		WO 98/16186	10/16/1996	ICN Pharmaceuticals		
W		WO 98/29108	12/30/1996	Andrew, P. Feinberg		Γ
		WO 98/54318	05/28/1997	Marie Curie Research		T
/S.G.L/				Institute		
Examiner		101		Date		
Signature	1	/Sharmila Landau/		Considered	07/03/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

•				Complete if Known		
Substitute f	or form 144	9/PTO		Application Number	10/698,983	
INFORM	ATION	DISC	LOSURE	Filing Date	10/31/2003	
			LICANT	First Named Inventor	Howard Sands	
(Use a	s many shee	is as ne	cessary)	Art Unit	1614	
			•	Examiner Name	Not yet assigned	
Sheet	3	of	5	Attorney Docket Number	12636-304.201	

		FOREIGN	PATENT DO	CUMENTS	•	
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code' - Number' - Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
		WO 00/05419	07/24/1998	Yeda Research and		
/S.G.L/				Development]	
				Company Ltd.		
		WO 00/23112	10/19/1998	Methylgene, Inc.		Γ
		WO 00/40269	01/05/1999	Clarence Lee		T
		WO 00/54574	03/18/1999	The University of Chicago		
		WO 00/62075	04/13/1999	Rutgers, The State University of New Jersey		
		WO 01/21215 A1	09/22/1999	Ortho-McNeil Pharmaceutical, Inc.		
		WO 01/69262 A1	03/15/2000	University of Massachusetts		
		WO 01/79164 A2	03/21/2000 09/01/2000 09/08/2000	Atherogenics, Inc. Bionomics Limited		
		WO 02/18592 A1				
		WO 02/21140 A1		Metabolic Engineering Laboratories Co., Ltd.		
		WO 02/051980 A2	12/12/2000	Nucleus Remodeling, Inc.		
		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		T
		WO 02/069903 A3	03/06/2001	Biocryst Pharmaceuticals, Inc.		
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		T
		WO 02/083705 A1	04/13/2001	The Johns Hopkins University School of Medicine	. *	
\/		WO 02/085400 A1	04/24/2001	Supergen, Inc.		T
WO 02/087586 A1		WO 02/087586 A1	04/26/2001	Control Delivery Systems, Inc.		Ť
/S.G.L/		WO 03/006950 A2	07/12/2001	Geron Corporation		T
Examiner Signature		/Sharmila Landau/	 	Date Considered	07/03/2007	

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for form 1449/PTO				Application Number	10/698,983	
INFORM	MATION	DISC	LOSURE	Filing Date	10/31/2003	
STATEMENT BY APPLICANT				First Named Inventor	Howard Sands	
(Use a	(Use as many sheets as necessary)			Art Unit	1614	
				Examiner Name	Not yet assigned	
Sheet	4	of	5	Attorney Docket Number	12636-304.201	

Examiner Cite Initials* No.		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	76
		Country Code" - Number" - Kind Code" (If known)			Relevant Figures Appear	
/S.G.L/		WO 03/012112 A1	07/27/2001	Geneinvent BBL AB		
		WO 03/012085 A1	07/30/2001	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.		
		WO 03/011209 A2	07/31/2001	Yeda Research and Development Co. Ltd.		
		WO 03/026574 A2	09/24/2001	AU, Jessie, L. –S.		
		WO 03/031932 A2	10/05/2001	Case Western Reverse Univresity		
		WO 03/040363 A1	11/08/2001	Japan Science and Technology Corporation		
		WO 03/043631 A2	11/23/2001	F. Hoffman-LA Roche AG		
	WO 03/045427 A2 WO 03/046190 A1		11/29/2001	Dandrit Biotech A/S		Τ
			11/30/2001	Medigene Aktiengesellschaft		
		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		Τ
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 03/086374 A1	04/05/2002	University of Utah Research Foundation		
		WO 2003/087774 A3	04/12/2002	Gurators of the University of Missouri		
$\overline{\mathbf{V}}$		WO 03/104427 A2	06/05/2002	Case Western Reserve University		
/S,G,L/		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		
Examiner Signature		/Sharmila Landau/		Date 07	/03/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute	for form 144	49/PTO		Application Number	10/698,983		
			LOSURE	Filing Date	10/31/2003		
STATEMENT BY APPLICANT				First Named Inventor	Howard Sands		
(Use	as many shee	els as nece	essary)	Art Unit	1614		
				Examiner Name	Not yet assigned		
Sheet	5	of	5	Attorney Docket Number	12636-304.201		

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
Can		VON HOFF, et al., "5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia," Annals of Internal Medicine (1976) 85(2), pages 237-245						
	-7							

		Λ			
Examiner	1.0 20.	26.1	Date .	· A	0.1 60
signature		monday	Considered	6	13/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP our. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.